title: A novel melanoma-targeting peptide screened by phage display exhibits antitumor activity.
abstract: Peptide display on the phage surface has been widely used to identify specific peptides targeting several in vivo and in vitro tumor cells and the tumor vasculature, playing a role in the discovery of bioactive antitumor agents. Bioactive peptides have been selected to target important tumor receptors or apoptosis-associated molecules such as p53. Presently, we attempted to identify potentially antitumor bioactive molecules using the whole cell surface as the recognizable static matrix. Such methodology could be advantageous in cancer therapy because it does not require previous characterization of target molecules. Using a C7C phage display library, we screened for peptides binding to the B16F10-Nex2 melanoma cell surface after pre-absorption on melan-A lineage. After a few rounds of enrichment, 50 phages were randomly selected, amplified, and tested for inhibition of tumor cell proliferation. Seven were active, and the corresponding peptide of each phage was chemically synthesized in the cyclic form and tested in vitro. Three peptides were able to preferentially inhibit the melanoma lineage. A unique peptide, [-CSSRTMHHC-], exhibited in vivo antitumor inhibitory activity against a subcutaneous melanoma challenge, rendering 60% of mice without tumor growth. Further, this peptide also markedly inhibited in vitro and in vivo the tumor cell invasion and cell-to-cell adhesiveness in vitro. This is the first report on a bioactive peptide derived from a C7C library active against whole melanoma cells in vitro and in vivo.
authors.affiliation: Experimental Oncology Unit (UNONEX), Department of Microbiology, Immunology and Parasitology, Federal University of São Paulo, Rua Botucatu 862, oitavo andar, São Paulo, São Paulo 04023-062, Brazil. almatsuo@unifesp.br
authors.forename: Alisson L
authors.initials: AL
authors.lastname: Matsuo
authors.forename: Aparecida S
authors.initials: AS
authors.lastname: Tanaka
authors.forename: Maria A
authors.initials: MA
authors.lastname: Juliano
authors.forename: Elaine G
authors.initials: EG
authors.lastname: Rodrigues
authors.forename: Luiz R
authors.initials: LR
authors.lastname: Travassos
mesh_terms: D000595:Amino Acid Sequence; D000818:Animals; D000970:Antineoplastic Agents / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D015820:Cadherins / Q000378:metabolism; D002448:Cell Adhesion / Q000187:drug effects; D045744:Cell Line, Tumor; D019070:Cell Lineage / Q000187:drug effects; D049109:Cell Proliferation / Q000187:drug effects; D004195:Disease Models, Animal; D004354:Drug Screening Assays, Antitumor; D008545:Melanoma / Q000188:drug therapy*; D008546:Melanoma, Experimental / Q000188:drug therapy; D051379:Mice; D008810:Mice, Inbred C57BL; D008969:Molecular Sequence Data; D009361:Neoplasm Invasiveness; D019151:Peptide Library; D010456:Peptides, Cyclic / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D011485:Protein Binding / Q000187:drug effects; D013194:Staining and Labeling; D040521:Subcutaneous Tissue / Q000187:drug effects / Q000473:pathology; D014410:Tumor Stem Cell Assay
chemical_list: D000970:Antineoplastic Agents; D015820:Cadherins; D019151:Peptide Library; D010456:Peptides, Cyclic
references.citation: Nature. 1996 Mar 28;380(6572):364-6
references.pmid: 8598934
references.citation: Cancer Res. 2006 Jan 1;66(1):34-40
references.pmid: 16397212
references.citation: Neoplasia. 2007 Sep;9(9):723-33
references.pmid: 17898868
references.citation: Bioconjug Chem. 2007 Nov-Dec;18(6):1739-48
references.pmid: 17907769
references.citation: Cancer Res. 2009 Jun 15;69(12):5030-8
references.pmid: 19491271
references.citation: Hepatology. 2009 Nov;50(5):1453-63
references.pmid: 19676131
references.citation: C R Acad Sci III. 1993 Sep;316(9):813-21
references.pmid: 8076212
references.citation: Nucl Med Biol. 2000 Nov;27(8):815-25
references.pmid: 11150716
references.citation: Mol Cancer Ther. 2003 Mar;2(3):295-300
references.pmid: 12657724
references.citation: Mol Cancer. 2007 Jul 09;6:44
references.pmid: 17620116
references.citation: Cancer Res. 2000 Dec 1;60(23):6551-6
references.pmid: 11118031
references.citation: Drug Discov Today. 2002 Nov 15;7(22):1138-43
references.pmid: 12546857
references.citation: Science. 1990 Jul 27;249(4967):386-90
references.pmid: 1696028
references.citation: Eur J Biochem. 2001 Apr;268(7):2004-12
references.pmid: 11277922
references.citation: Science. 2000 Aug 18;289(5482):1197-202
references.pmid: 10947988
references.citation: FASEB J. 2005 Dec;19(14):1978-85
references.pmid: 16319141
references.citation: Curr Opin Chem Biol. 2001 Jun;5(3):308-13
references.pmid: 11479123
references.citation: Tumour Biol. 2009;30(3):130-40
references.pmid: 19546606
references.citation: Drug Discov Today. 2004 Jun 15;9(12):525-9
references.pmid: 15183160
references.citation: Hybrid Hybridomics. 2002 Oct;21(5):321-31
references.pmid: 12470474
references.citation: Anal Biochem. 2001 May 15;292(2):257-65
references.pmid: 11355859
references.citation: Cancer Immunol Immunother. 2007 May;56(5):677-87
references.pmid: 16967280
references.citation: Ann Hematol. 2002;81 Suppl 2:S66-7
references.pmid: 12611081
references.citation: Clin Immunol Immunopathol. 1996 May;79(2):105-14
references.pmid: 8620616
references.citation: Cancer Lett. 2001 Oct 10;171(2):153-64
references.pmid: 11520599
references.citation: Nat Protoc. 2006;1(5):2315-9
references.pmid: 17406473
references.citation: Biochem Biophys Res Commun. 2006 Mar 24;341(4):964-72
references.pmid: 16458253
references.citation: Mol Med. 2007 May-Jun;13(5-6):246-54
references.pmid: 17622312
references.citation: N Engl J Med. 2006 Jul 6;355(1):51-65
references.pmid: 16822996
references.citation: J Biosci. 2009 Jun;34(2):213-20
references.pmid: 19550037
references.citation: FASEB J. 2003 Feb;17(2):256-8
references.pmid: 12490548